ArticleMolecular medicine (Cambridge, Mass.)2025
AREG
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Elevated ST2Arthritis research & therapy · 2026Article
- Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation.Frontiers in cardiovascular medicine · 2026Review
- Integrated Multi-Omics Analyses Identify TYMP as a Candidate Protective Immunoregulatory Marker in CD4⁺ T Cells During Sepsis.Journal of inflammation research · 2026Article
- A review of epidermal growth factor receptor ligands in glucose homeostasis.Frontiers in endocrinology · 2026Review
- A stage-based framework to interpret regulatory T cell biology after heart transplantation.Frontiers in cardiovascular medicine · 2026Review
- The DBC1-HIF-1α-PPAR-γ axis regulates Treg cell differentiation to promote myocardial fibrosis in experimental diabetic cardiomyopathy through the paracrine secretion of Areg.Frontiers in endocrinology · 2026Article
- Immune Mechanisms in Myocardial Remodeling Following Myocardial Infarction: Focusing on Regulatory Networks of T Cell Responses.Journal of inflammation research · 2026Review
- The emerging role of tissue regulatory T cells in tissue repair and regeneration.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancing tissue repair and angiogenesis post-Acute myocardial infarction (AMI) is critical to improving cardiac function and preventing heart failure. Recent studies have highlighted the interaction between immune cells and endothelial cells in post-AMI angiogenesis, yet the specific contributions of different immune cell subsets remain poorly understood. Emerging evidence suggests the presence of a subset of regulatory T cells (Tregs) expressing Amphiregulin (AREG) in infarcted myocardial tissue, with AREG acting as a paracrine protein that plays a key role in angiogenesis. However, whether AREG⁺ Tregs mediate post-AMI angiogenesis and the underlying molecular mechanisms remain unclear. In this study, we demonstrate that Treg activation promotes tissue repair and improves cardiac function after AMI, although it does not significantly impact angiogenesis or endothelial cell behaviors. Notably, overexpression of AREG⁺ Tregs stimulates robust neovascularization post-AMI, reduces myocardial fibrosis, and further enhances cardiac function. Our in vitro data reveal that AREG⁺ Tregs secrete not only AREG but also angiogenic factors such as VEGF and FGF, which promote endothelial cell proliferation, migration, and tube formation. RNA sequencing analysis identifies FoxM1 as a key regulator of this angiogenic process in cardiac microvascular endothelial cells (CMECs). Importantly, inhibition of AREG in Tregs abolishes the FoxM1-dependent angiogenic response.In summary, we identified AREG⁺ Tregs as a distinct cell population driving neovascularization post-AMI, with FoxM1-mediated angiogenesis in CMECs. This may provide a foundation for harnessing specific Treg subsets for cardioprotection following AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.